These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 689078)

  • 1. The effects of elevating gamma-amino butyrate content in the substantia nigra on the behaviour of rats.
    Matsui Y; Kamioka T
    Eur J Pharmacol; 1978 Aug; 50(3):243-51. PubMed ID: 689078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines.
    Matsui Y; Kamioka T
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Dec; 305(3):219-25. PubMed ID: 33340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition by apomorphine of the potassium-evoked release of [3H]-gamma-aminobutyric acid from the rat substantia nigra in vitro.
    Arbilla S; Kamal LA; Langer SZ
    Br J Pharmacol; 1981 Oct; 74(2):389-97. PubMed ID: 7317688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turning behaviour induced by injection of muscimol or picrotoxin into the substantia nigra demonstrates dual GABA components.
    Reavill C; Jenner P; Leigh N; Marsden CD
    Neurosci Lett; 1979 May; 12(2-3):323-8. PubMed ID: 460728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA.
    Hill JM
    Brain Res; 1985 Sep; 342(1):18-25. PubMed ID: 4041811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of GABAergic drugs on dopamine catabolism in the nigrostriatal and mesolimbic dopaminergic pathways of the rat.
    Gundlach AL; Beart PM
    J Pharm Pharmacol; 1981 Jan; 33(1):41-3. PubMed ID: 6114152
    [No Abstract]   [Full Text] [Related]  

  • 8. Alterations in apomorphine concentration in spinal cord and brain follow the time course of catalepsies induced by different treatments.
    Kolasiewicz W; Harasiewicz A; Melzacka M; Wolfarth S
    Exp Neurol; 1983 Jul; 81(1):195-209. PubMed ID: 6861947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between dopamine and gamma-aminobutyrate in the substantia nigra: implications for the striatonigral output hypothesis.
    Starr MS; Summerhayes M; Kilpatrick IC
    Neuroscience; 1983 Mar; 8(3):547-59. PubMed ID: 6856085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of chronic haloperidol and sulpiride treatment on nigral and striatal GABA content.
    Nicoletti F; Patti F; Condorelli DF; Rampello L; Giammona G; Di Giorgio RM; Canonico PL; Scapagnini U
    J Neurochem; 1981 Oct; 37(4):1048-51. PubMed ID: 7320718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gabaculine, a new potent inhibitor of gamma-amonobutyrate transaminase, on the brain gamma-amonobutyrate content and convulsions in mice.
    Matsui Y; Deguchi T
    Life Sci; 1977 Apr; 20(7):1291-5. PubMed ID: 850479
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of GABA in the substantia nigra.
    James TA; Starr MS
    Nature; 1978 Sep; 275(5677):229-30. PubMed ID: 692697
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of dopamine agonists on gamma-aminobutyric acid (GABA) turnover in the superior colliculus: evidence that nigrotectal GABA projections are under the influence of dopaminergic transmission.
    Melis MR; Gale K
    J Pharmacol Exp Ther; 1983 Aug; 226(2):425-31. PubMed ID: 6875856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal by apomorphine of the gabaculine-induced GABA accumulation in mouse cortex.
    Steulet AF; Hauser K; Martin P; Leonhardt T; Bandelier V; Gunst F; Bernasconi R
    Eur J Pharmacol; 1989 Dec; 174(2-3):161-70. PubMed ID: 2630298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute changes in nigral substance P content induced by drugs acting on dopamine, muscarine and GABA receptors.
    Koshiya K; Kato T
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):223-7. PubMed ID: 6197660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. gamma-Aminobutyric acid: the essential mediator of behaviour triggered by neostriatally applied apomorphine and haloperidol.
    Cools AR; Janssen HJ
    J Pharm Pharmacol; 1976 Jan; 28(1):70-4. PubMed ID: 6658
    [No Abstract]   [Full Text] [Related]  

  • 17. A simple approach to study the effect of haloperidol on GABA functional activity in the nigro-striatal system.
    Cattabeni F; Maggi A; DeAngelis L; Bruno F; Racagni G
    J Neurochem; 1977 Jun; 28(6):1407-8. PubMed ID: 874507
    [No Abstract]   [Full Text] [Related]  

  • 18. Biphasic and opposite effects of dopamine and apomorphine on endogenous GABA release in the rat substantia nigra.
    van der Heyden JA; Venema K; Korf J
    J Neurochem; 1980 Jan; 34(1):119-25. PubMed ID: 6778956
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
    Yamamoto BK; Nash JF; Gudelsky GA
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1063-70. PubMed ID: 7791076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine 3',5'-cyclic monophosphate as a possible mediator of rotational behaviour induced by dopaminergic receptor stimulation in rats lesioned unilaterally in the substantia nigra.
    Satoh H; Satoh Y; Notsu Y; Honda F
    Eur J Pharmacol; 1976 Oct; 39(2):365-77. PubMed ID: 185065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.